- Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
- Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- Janux Therapeutics Announces Proposed Public Offering of Common Stock
- Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors
More ▼
Key statistics
On Tuesday, Janux Therapeutics Inc (JANX:NMQ) closed at 45.49, -30.66% below its 52-week high of 65.60, set on May 03, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 46.84 |
---|---|
High | 48.44 |
Low | 45.22 |
Bid | 44.60 |
Offer | 47.99 |
Previous close | 47.99 |
Average volume | 981.31k |
---|---|
Shares outstanding | 51.85m |
Free float | 46.92m |
P/E (TTM) | -- |
Market cap | 2.49bn USD |
EPS (TTM) | -1.22 USD |
Data delayed at least 15 minutes, as of May 21 2024 21:00 BST.
More ▼